Blog
RSS FeedPosted by Michael Wonder on 22 Nov 2017
Re-evaluating eligibility criteria for oncology clinical trials: analysis of investigational new drug applications in 2015
22 November 2017 - Clinical trial eligibility criteria are necessary to define the patient population under study and improve trial safety. ...
Posted by Michael Wonder on 22 Nov 2017
Broadening eligibility criteria to make clinical trials more representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research Statement
22 November 2017 - Excessive or overly restrictive eligibility criteria can slow trial accrual, jeopardise the generalisability of results, and limit ...
Posted by Michael Wonder on 22 Nov 2017
Mendelian randomisation
21 November 2017 - Mendelian randomisation uses genetic variants to determine whether an observational association between a risk factor and an ...
Posted by Michael Wonder on 14 Nov 2017
The “utility” in composite outcome measures
14 November 2017 - Measuring what is important to patients. ...
Posted by Michael Wonder on 13 Nov 2017
Nearly half of recent EU approvals based on a single pivotal study
10 November 2017 - A recent study found that 45% of marketing authorizations granted in the EU from 2012 to ...
Posted by Michael Wonder on 16 Oct 2017
Cancer drug study data was falsified, says AstraZeneca
14 October 2017 - An early lab study supporting a cancer drug bought by British drugmaker AstraZeneca was falsified, the ...
Posted by Michael Wonder on 10 Oct 2017
Gatekeeping strategies for avoiding false-positive results in clinical trials with many comparisons
10 October 2017 - Clinical trials characterizing the effects of an experimental therapy rarely have only a single outcome of interest. ...
Posted by Michael Wonder on 17 Sep 2017
Cheaper drug trials would lower prices: FDA chief
15 September 2017 - Decreasing the time and cost it takes to develop a drug would lower drug prices, FDA ...
Posted by Michael Wonder on 06 Sep 2017
Randomised, controlled trials in health insurance systems
6 September 2017 - The well-recognised limitations of traditional randomised, controlled trials, including their cost, the nature of the patients and ...
Posted by Michael Wonder on 04 Sep 2017
Statistical and clinical significance
4 September 2017 - In published research, a statistically significant result is often wrongly interpreted as representing a clinically important ...
Posted by Michael Wonder on 24 Aug 2017
Major new measures to help combat rare cancers
24 August 2017 - The Australian Government is supporting major new initiatives that will improve access to clinical trials, particularly for ...
Posted by Michael Wonder on 22 Aug 2017
What should patients be told about non-inferiority studies?
21 August 2017 - A non-inferiority trial is a study in which a new treatment is compared with an existing, already ...
Posted by Michael Wonder on 13 Aug 2017
A cancer conundrum: too many drug trials, too few patients
12 August 2017 - With the arrival of two revolutionary treatment strategies, immunotherapy and personalised medicine, cancer researchers have found ...
Posted by Michael Wonder on 02 Aug 2017
Evidence for health decision making — beyond randomised, controlled trials
2 August 2017 - A core principle of good public health practice is to base all policy decisions on the highest-quality ...
Posted by Michael Wonder on 29 Jul 2017
Pharmaceutical companies’ policies on access to trial data, results, and methods: audit study
26 July 2017 - Goldacre et al. set out to identify the policies of major pharmaceutical companies on transparency of trials, ...